Sector News

Concordia Healthcare to buy some assets of Covis Pharma for $1.2 bln

March 10, 2015
Life sciences
(Reuters) – Concordia Healthcare Corp, which makes drugs for rare diseases and devices for diabetic patients, said it would buy some assets of privately held Covis Pharma Holdings SARL for $1.2 billion in cash.
 
Concordia said the drug portfolio it will acquire consists of 18 branded generic products, including generic drugs for heart diseases, neurological disorders and cancer.
  
Covis expects the portfolio to generate revenue of $140 million to $145 million in 2014, with gross margin of about 90 percent, Concordia said.
 
Concordia expects the deal to add over 50 percent to adjusted earnings in 2015.
 
The company reported a profit in the third quarter of 2014 after two quarters of losses. Overall it earned about $7.9 million in the first three quarters of 2014.
 
Oakville, Ontario-based Concordia said the drug portfolio is part of the two Covis units it is acquiring, Covis Pharma SARL and Covis Injectables SARL – both headquartered in Switzerland.
 
Covis Pharma Holdings, the parent company, is controlled by affiliates of Cerberus Capital Management L.P., Princeton Biopharma Capital Partners LLC and Bourne Partners.
 
RBC Capital Markets is Concordia’s financial adviser, and Sullivan & Cromwell LLP and Fasken Martineau DuMoulin LLP is its legal counsel.
 
Lowenstein Sandler LLP is Covis’ legal counsel, and Bourne Partners served its financial adviser. (Reporting by Sneha Banerjee in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.